



Important News from the San Antonio Metropolitan Health District (SAMHD)

May 21, 2010

Survey of Interest for New VFC Vaccines

The San Antonio Metropolitan Health District's Vaccines for Children (VFC) Program is seeking to determine provider interest in two vaccines recently approved by the FDA and added to the CDC vaccine contract. They are **Cervarix**[®] (GlaxoSmithKline) which is a bivalent (Types 16 & 18) Human Papillomavirus (HPV) vaccine; and **Menveo**[®] (Novartis Vaccines and Diagnostics) which is a Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine.

In order to plan for the addition of these vaccines to SAMHD's CDC vaccine allocation plan, we are providing this brief survey so that those practices that have an interest in providing any of these vaccines to their VFC-eligible patients can indicate that to us. These vaccines are covered under the CDC ACIP-VFC Resolutions for the prevention of HPV and meningococcal diseases. It is anticipated that these vaccines will be available for order in July; depending on supply. The following is a brief description of each vaccine.

CERAVARIX[®]

Cervarix[®] is a three-dose vaccine series (given at 0, 1-2, & 6 mos.) to prevent cervical cancer in females caused by human papillomavirus (HPV). Although it is routinely recommended for females 11-12 years of age, it is available for VFC-eligible females ages 9-18 years.

Note: With Cervarix[®] being a bivalent HPV product and different from the quadrivalent HPV product, Gardasil[®] (Merck), it has its own VIS. It is available at the following link:

<http://www.cdc.gov/vaccines/pubs/VIS/downloads/vis-hpv-cervarix.pdf>

MENVEO[®]

Menveo[®] (MCV4) is a single dose vaccine for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y and W-135. MCV4 is routinely recommended for children ages 11-12 years who have not previously received meningococcal conjugate vaccine. [See April 1, 2008 VFC memo to providers regarding specific recommendations and high-risk indication for MCV4]. Menveo[®] is also available for VFC-eligible patients ages 2-18 years.

Please complete the following survey by Friday, June 4, 2010 and fax it back to the VFC Program at (210) 922-9938. If you have any questions pertaining to this information, please contact Kenya Wilson (207-3974) or Anthony Johnson (207-4015) at the VFC Program.

VFC Cervarix and Menveo Vaccine Survey

Provider Name: _____ VFC Pin# _____

Person Completing Estimates: _____

Phone Number: _____

Email Address: _____

1.) Do you plan to order Cervarix®?

Yes

No

2.) # of Cervarix® doses you plan to order on a monthly basis for VFC eligible patients:

3.) Do you plan to order Menveo®?

Yes

No

4.) # of Menveo® doses you plan to order on a monthly basis for VFC eligible patients:
